Clinical trials: Inhalation
Chronic Obstructive Pulmonary Disease
Comparison of the Effects of Indacaterol and Tiotropium on Inspiratory Capacity
This study compared the effects of a single dose of indacaterol with that of a single dose of tiotropium on inspiratory capacity.
- Trial name
- NCT00999908
- Testing
- Indacaterol 150 μg, Tiotropium 18 μg
- Where
- 11 sites in Italy
- Volunteers
- 54 people
- Sponsor
- Novartis Pharmaceuticals
Healthy
Study of Single and Multiple Doses of PRS-220 Administered by Oral Inhalation in Healthy Subjects
A dose escalating study of PRS-220 administered by oral inhalation in healthy subjects
- Trial name
- NCT05473533
- Testing
- PRS-220
- Where
- Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Pieris Australia Pty Ltd
Diabetes Mellitus, Type 2
To Examine the Lung When People With Diabetes Take an Inhaled Form of Insulin, Compared to Subcutaneous Insulin.
To examine the lung when people with diabetes take an inhaled form of insulin, compared to subcutaneous insulin.
- Trial name
- NCT00143338
- Testing
- Inhaled insulin
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Pfizer
Chronic Obstructive Pulmonary Disease COPD
Efficacy, Pharmacokinetics (PK), Safety and Tolerability Study of Inhaled AZD8871
This is a study to evaluate the effects of AZD8871 in patients with COPD. Adult male or female patients with moderate to severe COPD, who agree to be in this study, will receive 3 treatments, i.e.
- Trial name
- NCT02971293
- Testing
- AZD8871 100 µg, AZD8871 600 µg
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 42 people
- Sponsor
- AstraZeneca
Asthma
Evaluation of Efficacy and Safety of E004 in Children With Asthma
This is a multi-center, randomized, double-blinded, placebo-controlled, parallel, 4-week study in 60 pediatric patients (4-11 years old) with asthma, comparing E004 with Placebo HFA-MDI in pediatric patients who are 4-11 years of…
- Trial name
- NCT01460511
- Testing
- E004 (Epinephrine Inhalation Aerosol) HFA-MDI
- Where
- 8 sites in United States
- Volunteers
- 70 people
- Sponsor
- Amphastar Pharmaceuticals, Inc.
Cystic Fibrosis
Study of INS37217 Inhalation Solution in Mild to Moderate Cystic Fibrosis Lung Disease
The purpose of this study is to assess the safety and effectiveness of multiple dosages of INS37217 compared to placebo over 28 days in subjects with mild to moderate cystic fibrosis (CF) lung disease.
- Trial name
- NCT00056147
- Testing
- denufosol tetrasodium (INS37217)
- Volunteers
- 90 people
- Sponsor
- Merck Sharp & Dohme LLC
Primary Ciliary Dyskinesia
Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia
To evaluate the safety and efficacy of treatment with VX-371 with and without ivacaftor, and the effect of VX-371 with and without ivacaftor on quality of life (QOL) in subjects with primary ciliary dyskinesia (PCD).
- Trial name
- CLEAN-PCD (NCT02871778)
- Testing
- VX-371, Hypertonic Saline, VX-371 + HS
- Where
- 34 sites in United States, Canada and 6 more
- Volunteers
- 123 people
- Sponsor
- Parion Sciences
Alpha 1-Antitrypsin Deficiency
Phase III, Efficacy and Safety of "Kamada-AAT for Inhalation"
The goal of this clinical trial is to learn if AAT for inhalation, at a dose of 80 mg/day can slow the progression of lung disease in people who have lung disease caused by severe genetic deficiency in Alpha 1 Antitrypsin (AATD).
- Trial name
- InnovAATe (NCT04204252)
- Testing
- Alpha 1-Antitrypsin
- Where
- 9 sites in Belgium, Finland and 4 more
- Volunteers
- 98 people
- Sponsor
- Kamada, Ltd.
MAC Lung Disease, Treatment Refractory MAC Lung Disease
ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension
This clinical trial is designed to compare the efficacy and safety of Clofazimine Inhalation Suspension versus placebo when added to guideline-based therapy (GBT)
- Conditions
- MAC Lung Disease, Treatment Refractory MAC Lung Disease, Mycobacterium Infections, Nontuberculous
- Trial name
- ICoN-1 (NCT06418711)
- Testing
- Clofazimine Inhalation Suspension
- Where
- 99 sites in United States, Australia and 3 more
- Volunteers
- 132 people
- Sponsor
- Mannkind Corporation
Pulmonary Disease, Chronic Obstructive
Pilot Study Comparing Tiotropium (Spiriva) to Salmeterol (Serevent) Plus Fluticasone (Flixotide) in Chronic Obstructive Pulmonary Disease (COPD)
The primary objective of this study is to estimate the comparative bronchodilator effect size and variability for tiotropium (Spiriva, 18 µg q.d.) with the free combination of salmeterol (Serevent, 50 µg b.i.d.) and fluticasone…
- Trial name
- NCT00239499
- Testing
- Tiotropium, Salmeterol plus Fluticasone
- Where
- 12 sites in South Africa
- Volunteers
- 107 people
- Sponsor
- Boehringer Ingelheim
COPD
Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to LABA/ICS
The primary objective is to compare the effectiveness of maintenance therapy initiation with the combination treatment Tiotropium and Olodaterol (Olo+Tio) compared with LABA/ICS combination in COPD as the time to the first COPD…
- Trial name
- NCT04138758
- Testing
- Tiotropium bromide + Olodaterol, LABA/ICS
- Where
- United States
- Volunteers
- 42,953 people
- Sponsor
- Boehringer Ingelheim
Breast Cancer
Evaluation of the Efficacy of Digital Breast Tomosynthesis Imaging
The primary objective of this protocol is to collect the 2-dimensional (2D) screening and diagnostic images, and 3-dimensional (3D) Digital Breast Tomosynthesis (DBT) scans from patient mammography examinations acquired on…
- Trial name
- DBT (NCT01373671)
- Testing
- SIEMENS INSPIRATION DIGITAL BREAST TOMOSYNTHESIS (DBT) SYSTEM
- Where
- United States
- Volunteers
- 764 people, healthy volunteers welcome
- Sponsor
- Siemens Medical Solutions USA - CSG
Mild or Moderate Asthma
Gemini Symbicort pMDI
The purpose of this study is to determine whether treatment with Symbicort for 12 weeks will improve lung function and symptoms of adults and adolescents with asthma.
- Trial name
- NCT00646516
- Testing
- budesonide/formoterol (Symbicort)
- Volunteers
- 615 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
A Phase 2 Study of MP-376 to Prevent Acute Exacerbations in Chronic Obstructive Pulmonary Disease (COPD) Patients
Patients with Chronic Obstructive Pulmonary Disease (COPD) suffer from frequent and recurrent acute exacerbations (AECB) which are associated with enormous healthcare expenditures and significant morbidity, specifically an…
- Trial name
- NCT00739648
- Testing
- MP-376
- Where
- 39 sites in United States
- Volunteers
- 322 people
- Sponsor
- Amgen
Cystic Fibrosis
Clearing Lungs With Epithelial Sodium Channel (ENaC) Inhibition in Cystic Fibrosis (CF)
The goal of the study is to evaluate the safety and tolerability of P-1037 and to determine whether the combination of P-1037 with hypertonic saline or P-1037 alone has a greater effect on lung function in patients with CF than…
- Trial name
- CLEAN-CF (NCT02343445)
- Testing
- P-1037, Hypertonic Saline, Saline
- Where
- 33 sites in United States
- Volunteers
- 142 people
- Sponsor
- Parion Sciences
COPD (Chronic Obstructive Pulmonary Disease)
Phase 1 PK Study of AERO-007, an Inhaled LABA+LAMA Combination for Nebulization Delivery in COPD Patients
This is a phase 1, single-dose, 2-period crossover study in healthy volunteers to compare the systemic pharmacokinetic (PK) profile of inhaled AERO-002 versus inhaled active comparator product.
- Trial name
- NCT07802730
- Testing
- AERO-002 (60 mcg), Glycopyrrolate (18 mcg)
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AeroRx Therapeutics Inc.
Chronic Obstructive Pulmonary Disease
Effect of Indacaterol on Inspiratory Capacity (IC)
This study is being conducted to assess the effect of indacaterol (150 μg o.d.) on inspiratory capacity (IC), using placebo and open label tiotropium (18 μg o.d.) as comparators in patients with moderate chronic obstructive…
- Trial name
- NCT01012765
- Testing
- Indacaterol, Tiotropium
- Where
- 21 sites in Germany
- Volunteers
- 173 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Comparing Efficacy and Safety of Inhaled SNG001 to Placebo
When people with asthma get respiratory virus such as a cold or flu it often increases asthma symptoms. The investigators will test the study medication to find out if it can prevent the virus spreading from the nose to the…
- Trial name
- NCT01126177
- Testing
- Interferon beta 1a
- Where
- United Kingdom
- Volunteers
- 300 people
- Sponsor
- Synairgen Research Ltd.
Chronic Obstructive Pulmonary Disease
Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD)
This is a Phase 3B, 12-week, multicenter, open-label study to evaluate the relationship between as-needed usage of albuterol eMDPI and Clinical Exacerbation-Chronic Obstructive Pulmonary Disease (CE-COPD) in adult participants at…
- Trial name
- NCT03256695
- Testing
- Albuterol sulfate (ABS)
- Where
- 40 sites in United States
- Volunteers
- 405 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Asthma
Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Moderate Persistent Asthma
The overall purpose of the trial is to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® inhaler (2.5 mcg and 5 mcg once daily in the evening) over 48 weeks, compared to placebo, in children…
- Trial name
- NCT01634139
- Testing
- Tiotropium low dose QD, Tiotropium high dose QD
- Where
- 79 sites in United States, Bulgaria and 14 more
- Volunteers
- 403 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.